Antiviral product
OwnerShouming Zhong, Hongwen Yuinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb Astragalus extract, or an active fraction thereof, for use as an antiviral in the treatment of hepatitis C.
Claims19
A selective single herb Astragalus alcoholic extract characterized in that the extract of Astragalus is purified by at least a factor of 10 with reference to dried raw plant material, exhibits anti-HCV activity in a replicon assay, and comprises at least one marker selected from the group consisting of:
- Astragaloside I;
- Formononetin-7-O-β-D-glucoside;
- and
- 3′-hydroxyl-formononetin-7-O-β-D-glucoside.
A method for producing a single herb extract of Astragalus which exhibits anti-HCV activity in a replicon assay, and which is purified by at least a factor of 10 with reference to dried raw plant material, and which is characterized in that it comprises at least one marker selected from the group consisting of:
- Astragaloside I;
- Formononetin-7-o-β-d-glucoside;
- and
- 3′-hydroxyl-formononetin-7-o-β-d-glucoside comprising:
- a. an alcoholic extraction (which may be repeated);
- b. an ethanol-water precipitation process (which may be repeated);
- and
- c. a systematic solvent fractionation step with a plurality of solvents of different polarity.
A selective single herb Astragalus alcoholic extract having a TLC fingerprint substantially as shown in at least one of FIG. 4, FIG. 5, and FIG. 6.
Dependencies are inferred from the claim text.